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Abstract
The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed
with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agala). Established in 2001, FOS provides
long-term data on agala safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical
management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease
variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high
prevalence of cardiac morbidity, and demonstrated correlations between ocular changes and Fabry disease severity. These FOS
data represent a rich resource with utility not only for description of natural history/therapeutic effects but also for exploratory
hypothesis testing and generation of tools for diagnosis/management, with the potential to improve future patient outcomes.
Keywords
agalsidase alfa, enzyme replacement therapy, Fabry disease, Fabry Outcome Survey, outcomes
Introduction
Fabry disease is an X-linked lysosomal storage disorder caused
by deficiency of the hydrolytic enzyme a-galactosidase A
(a-Gal A).1 The natural history of Fabry disease includes pro-
gressive accumulation of the ganglioside globotriaosylcera-
mide (Gb3) in cells and organs throughout the body, leading
to multisystem pathology and ultimately premature death in the
fourth or fifth decade from renal, cardiac, or cerebrovascular
complications.1-6 The specific inborn error of glycosphingoli-
pid catabolism is due to one or more of numerous possible
mutations of the GLA gene, which results in reduced or absent
enzyme activity.7 Historically in the general population, classic
Fabry disease has an estimated regional prevalence between
1:37 0008 in male newborns in northwestern Italy and
1:117 0009 among all newborns in Australia. However, recent
publications reporting results from newborn screening for
Fabry disease show a much higher prevalence when ‘‘atypical’’
Fabry disease mutations are included, ranging from 1:2900 to
1:39008,10-12 and up to 1:1400 in some regions.13 Fabry disease
was considered to primarily affect male hemizygotes, virtually
all of whom exhibit progressive kidney dysfunction14; how-
ever, female heterozygotes are not merely carriers of Fabry
disease but also can portray all the signs and symptoms of
Fabry disease, albeit with a later onset and more variable phe-
notype than that observed in males.4,5
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The Fabry Outcome Survey (FOS) is an international, obser-
vational, physician-directed registry sponsored by Shire for
patients diagnosed with Fabry disease who are either candi-
dates for or are receiving enzyme replacement therapy (ERT)
with agalsidase alfa (agala; Replagal, Shire Human Genetic
Therapies, Inc., Cambridge, Massachusetts),15,16 a human form
of a-Gal A produced in a cultured human cell line by gene
activation.17 FOS was established in 2001 with the aim of
broadening the understanding of the nature of Fabry disease
and improving clinical management of affected patients.16 As
of June 1, 2016, FOS includes data from 2962 patients with
Fabry disease. Since its inception 15 years ago, FOS has
yielded 47 peer-reviewed publications and made key contribu-
tions to the understanding and treatment of Fabry disease
(Table 1).
The aim of this review is to summarize the key attributes of
FOS and describe the major contributions to the understanding
and treatment of Fabry disease from FOS over its first 15 years.
Evolving Design of FOS
Since its inception in 2001, FOS has grown to include a total of
24 countries represented in the registry in 2016, with 22 coun-
tries actively participating (Figure 1). The FOS design factored
in knowledge of the natural history of Fabry disease at the time
of its inception, such as multiregional information on the
genetic component, epidemiology, and diversity of signs and
symptoms.1,2,4,5 For instance, sequential patient-level data on
specific clinical outcomes (such as kidney function and quality
of life [QOL]) from different FOS specialist centers were
pooled to attain a sufficient sample size.16 In patients receiving
agala ERT, treatment response is assessed at least every 6
months, whereas untreated patients are reviewed annually to
monitor disease progression. Hence, FOS facilitates study of
the natural history of this rare disease in a large and diverse
group and provides baseline data against which the effects of
agala ERT can be gauged. Further, the international
Table 1. Key Contributions of FOS.
Milestone Year(s)
Development and validation of FOS Mainz Severity Score Index 2004, 200618,19
Define clinical manifestations in female and pediatric patients 200620,21
Confirm high prevalence of cardiac morbidity 200722
Report changes over time in cause of death in patients with Fabry disease 200923
Establish and validate prognostic and severity scores for Fabry disease 2010, 201224,25
Establish incidence of Fabry disease variants and implications for clinical management 201426
Provide long-term data for morbidity and mortality of patients with Fabry disease treated with agala for 5 years 201527
Describe correlations between ocular changes and Fabry disease severity 201528
Abbreviations: agala, agalsidase alfa; FOS, Fabry Outcome Survey.
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Figure 1. Countries with centers participating in the Fabry Outcome Survey.
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distribution of participating FOS centers allows comparison of
outcomes between different areas to potentially identify geo-
graphic differences in the delivery, effectiveness, and safety of
treatment. In addition, FOS supports agala ERT efficacy
shown in short-term clinical trials by providing evidence for
long-term effectiveness and safety of agala in a real-world
setting.29
A key challenge when collecting data via a patient registry is
ensuring comprehensive data capture. Several steps were initi-
ated in 2005 to improve the completeness of FOS data capture,
namely (1) a focus on centers enrolling 20 patients, (2) con-
centration on a limited number of clinically relevant core vari-
ables (ie, Fabry disease–related signs and symptoms, pain,
QOL, height, weight, blood pressure [BP], serum creatinine,
urinary protein, and left ventricular mass), and (3) the intro-
duction of clinical research associates to facilitate data collec-
tion and handling by participating treatment centers.15
The physician assessments and patient questionnaires used
within FOS are reflective of the multisystem involvement of
Fabry disease and designed to capture multiple aspects of the
disease. Participating center staff are trained on the use of the
database, and guidelines produced by FOS working groups
promote uniform data collection. Adults and children partici-
pating in FOS undergo thorough and regular health checks,
including physical examination, vital sign measurements,
echocardiography, and clinical laboratory testing. Patient-
reported outcomes used in FOS by adult patients include the
Brief Pain Inventory,30 EuroQol 5-Dimensions question-
naire,31 and the general FOS questionnaire. In addition, women
are provided the Female FOS questionnaire, which aims to
identify potential early predictive factors for disease progres-
sion and severity in this patient group. Child health and social
effects are assessed with the FOS Paediatric Health and Pain
questionnaire (FPHPQ; adapted from the Brief Pain Inventory
and the general FOS questionnaire),32 whereas health-related
QOL is measured by the KINDL questionnaire.33
Fabry Outcome Survey Analyses and
Publications: Highlights of the Last 15 Years
Diagnosis, Disease Severity, and Mortality
A major attribute of FOS is the capacity to perform different
types of observational analyses. The first publication emanat-
ing from FOS reported on a cross-sectional analysis of baseline
data from a cohort of 366 patients across 11 European coun-
tries.16 The analysis revealed long delays from onset of symp-
toms to a correct diagnosis in both male and female patients
(13.7 and 16.3 years, respectively), demonstrated that the dis-
ease affects females as well as males, and showed that signs
and symptoms may be present from early childhood.16 These
findings were confirmed in a more recent cross-sectional anal-
ysis of 262 FOS patients residing in Austria, Germany, and
Switzerland, which also found that Fabry disease remained
underdiagnosed in these countries.34 Furthermore, this analysis
linked disease severity measured by the FOS Mainz Severity
Score Index (MSSI) to patient age (P¼ .0001).34 A subsequent
analysis of Spanish FOS patients found that they were diag-
nosed at a slightly earlier age of 11 years. Spanish patients had
a smaller proportion of organs involved, irrespective of sex,
although FOS-MSSI scores were worse in male patients.35
Before FOS, it was difficult to define genotype–phenotype
relationships because of extreme variability in the clinical phe-
notype, age of onset, and course of Fabry disease, even within
the same family. By extracting data from male patients in FOS
(to minimize nongenetic factors and avoid the large phenotypic
variability associated with Fabry disease in women), positive
correlations were found between age at FOS entry and FOS-
MSSI score, as well as the number of affected organs.36
In the 2007 cross-sectional analysis by Cybulla et al, invol-
vement of the kidneys or heart was the main cause of morbidity
and death in 75% of patients with Fabry disease.34 A cohort
study compared the causes of death in 42 FOS patients between
2001 and 2007 with that of their 181 non-FOS relatives who
had Fabry disease and had died previously (most before
2001).23 Among the 42 FOS patients, cardiac disease was the
main cause of death in both male (34%) and female (57%)
patients. In contrast, the principal causes of death among
Fabry-affected relatives before 2001 were renal failure in males
(42%) and cerebrovascular disease in females (25%). These
data suggest that renal disease is less important as a cause of
mortality in patients with Fabry disease now than in the past
and that the relative importance of cardiac disease has
increased, possibly reflecting recent improvements in the man-
agement of renal disease with supportive care and ERT.23
Longitudinal examination of FOS data also has demon-
strated real-world effectiveness and safety of agala 0.2 mg/kg
every other week in adults and children,3,37-40 its beneficial
effects on pain scores/QOL,41 and its effectiveness in patients
with Fabry nephropathy.42 In addition, findings from a retro-
spective FOS cohort analysis showed that 5 years of agala ERT
in FOS resulted in delayed onset of morbidity (estimated risk of
a composite morbidity event: *16% [*26% in males] in
patients treated with agala 0.2 mg/kg every other week vs
*45% for patients not treated with ERT at 24 months) and
mortality (estimated median survival for males: 77.5 vs 60
years, respectively), compared with a well-described and
closely matched external cohort of untreated patients.27
Cardiac Manifestations
Although there are characteristic signs and symptoms of Fabry
disease such as acroparesthesia, pain, gastrointestinal symp-
toms, and angiokeratomas that are commonly seen in patients
with Fabry disease, cardiac involvement is important because
of its association with premature death.16 Given its progressive
nature, all patients with classic Fabry disease will develop
characteristic signs and symptoms. These include cardiac man-
ifestations such as left ventricular hypertrophy (LVH) with
cardiomyopathy, myocardial fibrosis, and symptoms like
angina, palpitations, and dyspnea, which were reported fre-
quently among untreated men and women in the seminal
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cross-sectional analysis of FOS data.16 A larger analysis of
cardiac manifestations in 714 FOS patients from 11 countries
showed that untreated men and women had hypertrophic car-
diomyopathy reflecting the progressive nature of the disease
over time, with ongoing disease-related alterations such as
myocardial fibrosis and clinical symptoms including angina,
dyspnea, arrhythmias, and syncope.22 The presence of hyper-
trophic cardiomyopathy was associated with a statistically sig-
nificantly higher frequency of cardiac symptoms, arrhythmias,
and valvular heart disease. Multivariate logistic regression
analysis in untreated patients demonstrated that sex, age, and
renal function, but not BP, were independently related to LVH.
Cardiac disease accounted for 29% of all deaths and was the
most frequent reported cause of death in females.22 In patients
with Fabry disease not treated with ERT, LVH progression is
rapid and may be detected even within a relatively short follow-
up period of 6 months.43
Overall in FOS, onset of any cardiac symptom occurred
earlier in males than in females (31.5 vs 39.9 years, respec-
tively),22 as did documentation of LVH (38.0 vs 55.4 years,
respectively).16 Similarly, in a subanalysis of Taiwanese FOS
patients with LVH, cardiac symptoms appeared at an earlier
age in men with classic Fabry disease mutations than in
women, respectively (30.0 vs 49.6 years; P < .05).44 However,
baseline analysis of the late-onset cardiac variant GLA splicing
Fabry mutation, IVS4 þ919G>A, revealed that, unlike in clas-
sic Fabry disease, cardiac symptoms appeared at the same age
in males and females (55.9 and 57.4 years, respectively).44
Treatment with agala in FOS has shown that several cardiac
outcome measurements can improve and the progression of
reductions in cardiac function may be slowed (Table 2). In a
longitudinal analysis of 5 years of agala ERT in FOS, patients
with baseline LVH (defined as left ventricular mass index
[LVMI] 48 g/m2.7) had a sustained reduction in LVMI from
71.4 to 64.1 g/m2.7 (P ¼ .0111; Figure 2) and a significant
increase in midwall fractional shortening (MFS; a measure of
systolic function) from 14.3% to 16.0% (P ¼ .02) after 3 years
of treatment.3 From baseline to 5 years, 80.7% of patients
receiving agala ERT had a stable LVMI and 76.9% had stable
or improved MFS.3 Stable LVMI and MFS were also noted in
agala-treated patients without baseline LVH; this suggests that
when ERT is initiated before LVH has developed, these
patients are unlikely to develop cardiomyopathy.3 These results
were corroborated by a separate 5-year analysis that compared
FOS patients with an external cohort of untreated and closely
matched patients with Fabry disease (Table 2).27
Other analyses from FOS suggest that treatment-related
effects associated with agala ERT are not affected by the sex
of the patient. When FOS data were stratified by sex and exam-
ined over a 4-year agala treatment period, the extent of the
mean reduction in LVMI from baseline in 78 females with
preexisting LVH was similar to that in 172 male counterparts.37
These findings are consistent with those from a prospective,
single-center, open-label study of 36 women with sympto-
matic Fabry disease, showing that in the subgroup of women
with LVH at baseline, mean LVMI decreased from 89.4 to
66.5 g/m2.7 after 12 months of agala ERT (P < .001) and
remained at this lower level throughout 4 years of agala ERT.45
In 10 of the 11 women without LVH at baseline, LVMI
remained within the normal range after 4 years of agala ERT.45
Subanalysis of FOS agala ERT data by region has consis-
tently shown effects associated with treatment comparable with
those seen in the overall group.46,48 A retrospective analysis of
data prospectively collected from 45 adults who received agala
ERT for 10 years at a single German FOS center showed no
progression of cardiomyopathy against a range of structural
and functional end points.46 Agala ERT was associated with
improvements in heart failure classification by 1 class (22 of
42 evaluable patients), stable or improved angina scores (41 of
42 patients), no LVH development in patients without LVH at
treatment initiation, and significant reduction in LVMI among
male patients with LVH at treatment initiation.46 Another anal-
ysis showed that agala ERT stabilized left ventricular heart size
over a 4-year period in 33 Spanish patients participating in
FOS.48
In a 2004 cross-sectional analysis of FOS data, the
prevalence of uncontrolled hypertension (defined as BP
130/80 mm Hg) was 52.4% among 391 men and women with
Fabry disease (60 received agala ERT),49 which compares
unfavorably with a 23% prevalence of uncontrolled office BP
>130/80 mm Hg in 436 patients not from FOS with hyperten-
sion and chronic kidney disease but without Fabry disease.50
As is the case in other hypertensive patient populations, an
inverse relationship between BP and estimated glomerular fil-
tration rate (eGFR) in FOS has been described on several occa-
sions.49,51,52 Over the course of 2 years of agala ERT, a
significant decrease in both systolic and diastolic BP was
observed, accompanied by a stabilization of kidney function.49
In another analysis of 66 FOS patients with hypertension, sys-
tolic and diastolic BP were reduced after 5 years of agala
ERT, from mean (standard deviation) values of 131.9 (17.2)
and 80.7 (12.1) mm Hg to 123.3 (15.7) and 75.9 (11.4) mm Hg,
respectively.42 Hypertension and other cardiovascular diseases
have a shared epidemiology with chronic kidney disease due to
pathophysiologic connections between these disease states, and
their coexistence portends cardiovascular events and death.53
Data from FOS also suggest that Fabry disease may also accel-
erate the development and progression of coexisting heart and
chronic kidney disease via the accumulation of Gb3 in each
organ type.54 Retrospective data collected over 14 years in 25
men with Fabry disease indicated that stage 5 chronic kidney
disease (ie, glomerular filtration rate category G5 [kidney fail-
ure]) was a strong indicator of cardiovascular disease progres-
sion irrespective of the use of ERT.54 In contrast, ERT initiated
before kidney failure stabilized both cardiac and renal disease
in this cohort.54
Renal Manifestations
Renal manifestations are another major area of interest in Fabry
disease, because renal impairment is an important cause of
morbidity and mortality.14,34 Progressive decline in renal
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Table 2. Effects of Agala ERT on Cardiac and Renal Manifestations in FOS Analyses.
Analysis
ERT
Duration,
years n
Cardiac Manifestations LVMI Change From Baseline, g/m2.7
Treated Male Versus Female
Beck, Mol Genet Metab
Rep. 201527
5.2 Men, n ¼ 71 0.33 (SEM: 0.10)
Women, n ¼ 93 0.48 (SEM: 0.09)
Hughes, Mol Genet Metab.
201137
4 Men, n ¼ 45 2.5
Women, n ¼ 24 7.3a
Impact of Baseline LVH
Mehta, Lancet. 20093 5 With baseline LVH, n ¼ 32 7.3 (SD: 15.3)a
Without baseline LVH, n ¼ 25 1.8 (SD: 10.1)
Beck, Mol Genet Metab
Rep. 201527
5.2 With baseline LVH Men (n ¼ 29), 0.19 (SEM: 0.16)
Women (n ¼ 45), 0.77 (SEM: 0.14)
Without baseline LVH Men (n ¼ 42), 0.47 (SEM: 0.13)
Women (n ¼ 48), 0.19 (SEM: 0.11)
Hughes, Mol Genet Metab.
201137
4 Women with baseline LVH, n ¼ 12 8.49a
Women without baseline LVH, n ¼ 12 0.67
Whybra, Genet Med.
200945
4 Females with baseline LVMI >85 g/m2.7, n ¼ 9 40.0a
Females with baseline LVMI >60-85 g/m2.7, n ¼ 9 14.3a
Females with baseline LVMI >48-60 g/m2.7, n ¼ 8 7.3a
Females with baseline LVMI <48 g/m2.7, n ¼ 11 4.5a
Kampmann, Orphanet J
Rare Dis. 201546
10 With baseline LVH Males (n ¼ 15), 13.55a
Females (n ¼ 16), NAb
Without baseline LVH Males (n ¼ 6), NAb
Females (n ¼ 8), NAb
Renal Manifestations
Mean eGFR Change From Baseline,
mL/min/1.73 m2/year
Treated Male Versus Female
Feriozzi, Am J Nephrol.
200947
3 Men, n ¼ 115 2.66 (SD: 5.07)a
Women, n ¼ 50 1.20 (SD: 3.28)a
Mehta, Lancet. 20093 5 Men, n ¼ 103 3.17a
Women, n ¼ 47 0.89a
Feriozzi, Clin J Am Soc
Nephrol. 201242
≥ 5 Men, n ¼ 134 2.2 (95% CI: 2.8 to 1.7)a
Women, n ¼ 74 0.7 (95% CI: 1.4 to 0.0)
Impact of Comorbidity or Baseline eGFR
Beck, Mol Genet Metab
Rep. 201527
5.4 Baseline eGFR ≥ 60 mL/min/1.73 m2 Men (n ¼ 117), 1.68 (SEM: 0.19)
Women (n ¼ 111), 0.43 (SEM: 0.21)
Baseline eGFR <60 mL/min/1.73 m2 Men (n ¼ 18), 2.86 (SEM: 0.53)
Women (n ¼ 22), 0.36 (SEM: 0.42)
Feriozzi, Clin J Am Soc
Nephrol. 201242
≥ 5 Hypertensive, n ¼ 66 2.4 (95% CI: 3.1 to 1.7)a
Normotensive, n ¼ 142 1.2 (95% CI: 1.7 to 0.6)a
Baseline eGFR ≥ 90 mL/min/1.73 m2 Men (n ¼ 87), 2.6 (95% CI: 3.1 to 2.0)a
Women (n ¼ 19), 1.4 (95% CI: 2.6 to 0.1)a
Baseline eGFR 30-59 mL/min/1.73 m2 Men (n ¼ 15), 2.5 (95% CI: 3.9 to 1.1)a
Women (n ¼ 12), 0.5 (95% CI: 2.0 to 1.0)
Abbreviations: agala, agalsidase alfa; CI, confidence interval; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FOS, Fabry Outcome
Survey; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; NA, not available; SD, standard deviation; SEM, standard error of the mean.
a P < .05 versus baseline.
b Value not given, but authors stated change from baseline was not significant at 10 years.
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function occurs in approximately half of the patients in FOS;
requirement for renal transplantation or dialysis was reported in
17% of men and 1% of women in a cross-sectional study.16 One
analysis reported renal disease in 84% of FOS patients.41 Renal
involvement typically includes proteinuria, seen in 44% to 54%
of males and 33% to 41% of females.16,41 Among 366 FOS
patients (241 were receiving ERT), progression to renal failure
requiring renal transplant or dialysis was reported in 17% of
male and 1% of female patients.16
Data from FOS (Table 2) have provided supporting evidence
that agala ERT can stabilize or slow the progressive decline in
renal function typically seen in patients with untreated Fabry
disease,3,27,42,47,55,56 particularly in patients without severe renal
impairment before treatment.41 Over 3 years of agala ERT, male
and female patients had mean (standard deviation) changes in
eGFR of2.7 (5.1) and1.2 (3.3)mL/min/1.73m2/year, respec-
tively, with no significant change in proteinuria.42,47 During lon-
ger periods of treatment (mean [range]: 7.4 [5.0-11.2] years),
mean (95% confidence interval) changes from baseline in eGFR
were2.2 (2.8 to1.7; P < .01 vs baseline) mL/min/1.73 m2/
year in men and0.7 (1.4 to 0.0; P¼ .05 vs baseline) mL/min/
1.73 m2/year in women (Figure 3), with minimal change in pro-
teinuria levels and irrespective of therapy with angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers.42 One FOS analysis of patients who received 5 years of
treatment showed mean eGFR changes in men and women of
3.2 and 0.9 mL/min/1.73 m2/year, respectively.3 A separate
analysis retrospectively compared outcomes in FOS patients who
received 5 years of agala ERT with published outcomes in an
external cohort of untreated and closely matched patients with
Fabry disease and found that treated patients experienced slower
declines in renal function (Table 2).27
After 5 years of agala ERT, 66 patients with hypertension in
FOS showed a greater decline in renal function than 142 nor-
motensive patients (mean [95% confidence interval] change in
eGFR: 2.4 [3.1 to 1.7] vs 1.2 [1.7 to 0.6] mL/min/
1.73 m2/year, respectively; P < .01).42 In another analysis of
outcomes following 5 years of agala ERT, patients with better-
preserved renal function at baseline (eGFR 60 mL/min/
1.73 m2) had a mean (standard error of the mean) eGFR change
of 1.7 (0.2) mL/min/1.73 m2/year in males and 0.4 (0.2)
mL/min/1.73 m2/year in females; among patients with more
severe baseline renal impairment, mean (standard error of the
mean) eGFR change was 2.9 (0.53) mL/min/1.73 m2/year in
males, whereas eGFR showed little change in females, with a
minimal increase of 0.36 (0.42) mL/min/1.73 m2/year.27 This
advantage for patients on ERT with better-preserved eGFR is
consistent with the hypothesis that earlier therapy is better and
that this may be due to less renal sclerosis or scarring.
Among FOS kidney transplant recipients, those not receiv-
ing agala ERT had more severe renal impairment and protei-
nuria than those receiving agala ERT; over 2 years of ERT,
there was a decrease in eGFR (from 59.2 to 51.1 mL/min/1.73
m2) and proteinuria remained stable.57 A sensitivity analysis by
Beck et al that included patients who had received a renal
transplant or dialysis before FOS entry showed no substantial
differences from the results in the overall renal cohort, which
showed a slower decline in renal function over 5 years of agala
ERT than that seen in an untreated population.27
Neurologic Manifestations
The most frequently reported signs and symptoms of Fabry dis-
ease are neurological, seen in 84% of male and 79% of female
FOS patients in Europe.16 The most common neurological
symptom is neuropathic pain, occurring in 76% of male and
64% of female patients and beginning at a mean age of 9.4 years
in males and 16.9 years in females.16 One of the common early
symptoms of Fabry disease is acroparesthesia (burning, tingling,
or pricking sensations), which, along with small fiber peripheral
neuropathic pain, can substantially reduce QOL.5,58-60 Another
FOS analysis reported that mean age of onset for pain was
14.8 years in males and 19.8 years in females.60 Pain is an
important dimension affecting QOL; data from untreated men
and women in FOS showed significantly lower QOL than in an
age- and sex-matched population without Fabry disease.58 The
impact of agala ERT has been favorable; significant 12% to 32%
improvements in measures of QOL and pain, as well as signif-
icant decreases in pain prevalence and severity, have been
reported after 1, 2, 3, and 5 years of agala ERT.3,58,60
Fabry disease manifests in the central and peripheral ner-
vous system; perhaps the most devastating neurologic conse-
quence is stroke, which occurs at an increased prevalence and
at a younger age in the Fabry disease patient population com-
pared with the general population.61,62 Stroke is frequently
seen along with cardiovascular abnormalities including valvu-
lar heart disease, LVH, arrhythmia, or hypertension.61,63 One
analysis found that cerebrovascular events, including stroke
and transient ischemic attack/prolonged reversible ischemic
neurologic deficit, occurred more often in women than men
(27% and 12%, respectively), although the mean age at onset
of cerebrovascular events was higher in female than in male
patients (43.4 and 28.8 years, respectively).16 Characteristic
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Figure 2. Mean (standard deviation) change in LVMI in FOS patients
with baseline cardiac hypertrophy who were treated with agala.3 agala
indicates agalsidase alfa; FOS, Fabry Outcome Survey; LVMI, left ven-
tricular mass index.
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white matter changes in magnetic resonance imaging scans of
the brain have been described in patients from FOS who expe-
rienced ischemic stroke, as well as subcortical gray matter
lesions and the pulvinar sign (bilateral hyperintensities around
the pulvinar thalamic nuclei in the region of the posterior tha-
lamus).61,64 To date, no definitive evidence of a reduced inci-
dence of stroke in patients receiving agala ERT has been
published, although significant improvements in cerebral vas-
cular function have been noted.65-67
Auditory symptoms, including tinnitus and hearing loss, have
beendescribed in 57% ofmale and 47% of female FOSpatients.16
Hearingwas described as significantlyworse amongpatientswith
Fabry disease than in an age-matched general population,
althoughclinically relevant hearing impairmentwas noted in only
16% of patients.68 In a study of children in the FOS database,
subjective hearing impairment was reported by 33%, although
this was confirmed by audiometry in only 19% of children; tinni-
tus was reported by 44% and the presence of tinnitus was corre-
latedwith overall Fabrydisease severity.69This pattern of hearing
loss in patientswithFabry disease is similar to age-relatedhearing
loss seen in non-Fabry populations, but it starts at a younger age
and progresses more rapidly; it is more severe in males than in
females.68 Hearing loss was classified as sensorineural in most
patients, although a conductive component also was described in
some; acute hearing loss has also been described.68 Hajioff et al
examined the effects of agala ERT on hearing and concluded that
a median of *1 year of treatment resulted in stabilized or
improved hearing amongpatientswhohad not already progressed
to severe hearing loss.70 Significant improvements were noted
among patients with mild or moderate hearing loss before treat-
ment, whereas no significant changes were seen in patients who
had normal hearing or severe hearing loss before treatment.70
Other Manifestations
Gastrointestinal manifestations, including abdominal pain and
diarrhea, have been reported in 57% of male and 47% of female
patients in FOS16; another FOS analysis found gastrointestinal
involvement in 52% of patients (50% of adults and 61% of
children).71,72 The most common symptoms were abdominal
pain in 33% and diarrhea in 21% of patients.71,72 Roughly sim-
ilar to acroparesthesia, the median age at onset of earliest gastro-
intestinal symptoms was *13 years.72 Gastrointestinal
symptoms were seen at a lower prevalence after 1 and 2 years
of agala ERT, with the greatest improvements noted in chil-
dren.71,72 Furthermore, among children who did not have
abdominal pain before starting treatment, there were no reports
of abdominal pain as a new symptom during 2 years of ERT.71,72
Anemia is considered an important additional risk factor for
morbidity and mortality in patients with various comorbidities,
including renal,73 cardiac,74 and cerebrovascular75 disease. A
cross-sectional study by Kleinert et al found that anemia with
hemoglobin <11 g/dL was present in 34% of FOS patients (47%
of men and 20% of women).76 Anemia in patients with Fabry
disease is more common than in the general population and is
often seen in association with impaired renal function, heart
failure, and evidence of systemic inflammation (eg, elevated
C-reactive protein levels in blood),76 as well as in association
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with use of ACEIs.77 Anemia was more prevalent among
patients with eGFR <60 mL/min/1.73 m2 (61%) versus patients
with eGFR 60 mL/min/1.73 m2 (30%; P < .001).76 Among
those patients who received agala ERT, the median hemoglobin
concentration was stable over 2 years of therapy.76 Information
regarding the use of ACEIs was not provided in this study.
Dermatologic manifestations of Fabry disease have been
described in 78% of male and 50% of female patients in FOS.
Angiokeratomas have been reported in 66% of males and 36% of
females in FOS,78 appearing at a mean age of 17.9 years in males
and 29.1 years in females.16,78 Telangiectasias generally
appeared later and were reported in 23% of males and 9% of
females.78 Along with neurological pain and gastrointestinal
symptoms, angiokeratomas are common in children with Fabry
disease and may represent a dermatologic hallmark sign to aid in
the diagnosis.16 The presence of angiokeratomas along with
telangiectasias is considered characteristic although not specific
for the disease.78 Other dermatological signs associated with
Fabry disease are sweating abnormalities (hypohidrosis, hyper-
hidrosis, anhidrosis), peripheral edema, and lymphedema.78
Further, the presence of cutaneous vascular signs has been
shown to correlate with the severity of systemic involvement
of Fabry disease, including pain, renal impairment, and cardiac
and cerebrovascular abnormalities.78 Hypohidrosis is well
recognized as a hallmark feature of Fabry disease, but hyperhi-
drosis is also seen, especially in girls and women.78,79 Lidove
et al examined FOS data and found hyperhidrosis at an overall
prevalence of 9.2% (6.4% in males and 11.9% in females).79 The
mean (range) age at onset of hyperhidrosis was 34.6 (3.0-58.0)
years in males and 32.1 (3.4-66.6) years in females.79 The
authors suggested that hyperhidrosis, when present, may be a
helpful symptom to improve diagnosis, particularly in females.
Ocular manifestations of Fabry disease have been described
in patients from the FOS database; these include cornea verti-
cillata (whorl-like epithelial-to-subepithelial corneal opaci-
ties), tortuosity and occasional aneurysms of conjunctival and
retinal vessels, and a pathognomonic spoke-like Fabry poster-
ior cataract.28,80 These ophthalmological manifestations do not
result in visual impairment or symptoms, but the presence of
cornea verticillata in particular is a suggestive sign for Fabry
disease.80 Sodi et al described cornea verticillata in 73.1% of
males and 76.9% of females (across an age range of 3-71
years), tortuous ocular vessels in 48.7% of males and 21.9%
of females (P < .01 for males vs females; overall age range:
4-69 years), and Fabry cataract in 23.1% of males and 9.8% of
females (P ¼ .02; age range: 5-68 years).80 There were signif-
icant associations between the presence of ocular vessel tortu-
osity and disease severity (as measured by FOS-MSSI), eGFR
deterioration, and cardiac enlargement.80 An analysis of a
larger sample of adult FOS patients by Pitz et al reported
somewhat lower prevalences of eye findings: cornea verticil-
lata, 50.8% in men, 51.1% in women; tortuous ocular vessels,
24.6% in men, 16.0% in women; Fabry cataract, 7.9% in men,
5.7% in women.28 Eye manifestations were also more prevalent
among patients with null or missense Fabry mutations versus
patients with mild missense mutations or the p.N215 S mutation
associated with late-onset cardiac variant disease.28 In the adult
FOS population, Pitz et al found that the overall severity of
Fabry disease was associated with the presence of each of the
3 types of ocular changes (cornea verticillata, tortuous ocular
vessels, and Fabry cataract) as well as with null and missense
mutations; thus, the presence of ocular signs may be useful in
identifying patients at risk for more severe disease.28
Special Populations
Our expanding knowledge has led to increasing recognition
that women are not merely asymptomatic carriers of the muta-
tions that cause Fabry disease; instead, most females who are
heterozygous for Fabry-associated mutations display clinical
manifestations of the disease. Although symptom onset gener-
ally occurs at an older age than in males, female patients typi-
cally experience signs and symptoms of Fabry disease by their
third and fourth decades and severe manifestations may be seen
in girls and women.16,20 In an analysis of the FOS female
patient population, Deegan et al found that 77% had neurologic
features, 59% had cardiac manifestations, and 40% had self-
reported indications of renal involvement.20 As well as being
the most common, neurologic signs were the earliest ones to be
seen in female patients, at *16 years of age, whereas cardiac
and renal features were noted at an average age of 33.5 and 37.3
years, respectively.20 The most common specific signs and
symptoms were acute pain attacks in 57% of patients, angio-
keratoma in 40%, cornea verticillata in 40%, proteinuria in
35%, vertigo in 32%, chronic pain in 32%, and LVH in 26%.20
The Fabry disease phenotype in girls and women is variable.
Barba Romero et al examined the relationship in FOS patients
between phenotype and geographic location across Europe and
found that women living in northern European countries had
significantly higher a-Gal A enzyme activity, but also signifi-
cantly higher disease severity scores, than women in southern
European countries.81 These severity score differences were
significant for most of the general, neurological, and renal
FOS-MSSI subscores, but not for any of the cardiovascular sub-
scores.81 Women in northern Europe also had higher levels of
proteinuria than those in southern Europe.81 The authors specu-
lated that these differences may be attributable to the effects of
epigenetic or extragenetic factors (such as diet or other environ-
mental factors) on Fabry disease expression in women.81
An analysis of FOS data by Hughes et al demonstrated that
the effectiveness of 4 years of agala ERT in women was com-
parable with that in men, with similar improvements in a vari-
ety of signs and symptoms, including cardiac structure and
function, and for a number of measures of pain, health-
related QOL, and renal function.37
Ramaswami et al examined data from children (<18 years of
age) in FOS and found that mean age at Fabry diagnosis was
*10 years, with a mean delay between symptom onset and
diagnosis of *3 years.21 The most common manifestations
were neurological and gastrointestinal signs and symptoms,
reported in *80% and *60% of children, respectively.21
Symptoms were noted at a similar frequency in boys and girls,
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although symptom onset occurred 2 to 5 years later in girls than
in boys.21 Recently, the FPHPQ has been developed and vali-
dated, which allows quantitative assessment of patient-reported
Fabry disease symptoms in children, making it a useful instru-
ment to monitor disease progression and treatment effects.32
Data from FOS have provided evidence of the effectiveness
and safety of agala in children, including safety in those <7 years
of age.38 A good response to agala has been demonstrated in
children, with benefits including improvements in pain scores
and QOL measures, as well as stabilization of cardiac and renal
parameters.39,40 Improvements in measures of pain and QOL
were seen in a 23-week open-label study of children 3.5 to
18.0 years of age.40 It is hoped that long-term follow-up of
children in FOS will provide evidence regarding whether early
initiation of ERT in childhood can inhibit the development of
serious Fabry disease complications later in life.
Discussion and a Look to the Future
Some of the key challenges in maintaining FOS over the last 15
years and beyond arise from the importance of facilitating data
quality and the evolution of the FOS governance system. The
FOS steering committee is well balanced across medical spe-
cialties and geographic regions, enabling a broad approach to
the rich data generated by FOS. Additionally, task forces are
established to address specific topics and generate publications
representing valuable scientific contributions in defined time
frames, thus translating the FOS data collection work into tan-
gible benefits. As described in detail by others,15,82 there are
inherent limitations of any registry data that create challenges
for working with these data. These limitations include patient
enrollment bias (patients with more severe symptoms or who are
receiving treatment are more likely to be enrolled in a registry),
lack of data completeness, and uncertain quality of data (because
assessments may not be standardized across participating
sites).15,82 As described in the Evolving Design of FOS section
earlier in this article, several measures aimed at improving FOS
data capture and handling have been undertaken.
However, particularly with a rare disease affecting rela-
tively small numbers of patients, FOS data offer a resource
with utility not only for description of natural history and ther-
apeutic effects but also for exploratory hypothesis testing and
the generation of tools for diagnosis and management. Disease
heterogeneity and understanding of the relative contribution of
underlying mutations in the a-Gal A gene and other genetic and
environmental factors to clinical severity require sophisticated
scoring techniques. The Fabry International Prognostic Index, a
prognostic severity score, was developed using data from FOS
patients and allows the use of early features to differentiate
patients with different probabilities of clinically significant
events.24 Age-adjusted FOS-MSSI severity scores have been
developed and validated, which correct for the effect of age and
sex on disease severity; this allows meaningful comparison of
disease severity between population subgroups (eg, different
genotypes) without confounding by factors such as age and
sex.25 Mean scores for genotypes can be generated and outliers
interrogated for additional factors contributing to their presen-
tation. As described in the Special Populations section earlier,
the FPHPQ is another instrument that has come out of FOS.32 A
recent report by Terryn et al describing the phenotype and impli-
cations of the GLA p.Ala143Thr mutation is an example of
patient management learning from FOS data.83 Observations
from FOS patient data were compared with information from
patient charts and the published literature and allowed the inves-
tigators to characterize this mutation as possibly pathogenic.83
Hypothesis generation by FOS may help direct future
research (for example, in areas such as genotype-phenotype cor-
relations and the growing but still poorly defined use of biomar-
kers). FOS and other interventional data can also support the
concept of timely initiation of ERT before the onset of irrever-
sible organ involvement in Fabry disease to prevent or stabilize
organ deterioration before irreversible escalation of tissue dam-
age and the expanding use of newborn screening to identify
patients, as well as helping to further define the correlation
between classic Fabry disease and that associated with late-
onset or oligosymptomatic mutations, which may account for
86% to 92% of Fabry disease cases identified by newborn
screening.8,84,85 Unresolved questions remain around issues such
as patients who show an apparent lack of response to therapy
(nonresponders) and the detection of alterations in survival.
The past 15 years of FOS typify a successful international
cooperative effort, whereas the future of FOS offers additional
opportunities for value in site-specific or country-specific per-
formance metrics, the potential to explore mutation-specific
information, the power of serial longitudinal measurements,
and the ability to track an evolving natural (and treated) history
over time. Although we recognize that there are limitations
associated with a registry database such as FOS, in particular
regarding data completeness and accuracy, this volume of real-
world data from a critical mass of participating centers can
function to stimulate and direct future areas of research.
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